丸美生物: 广东丸美生物技术股份有限公司关于使用部分闲置募集资金进行现金管理的公告

Core Viewpoint - The company plans to use up to RMB 200 million of idle raised funds for cash management to improve fund utilization efficiency while ensuring that it does not affect the normal operation of fundraising projects [1][4][6]. Fundraising Basic Situation - The company raised a total of RMB 842.14 million from its initial public offering, with a net amount of RMB 790 million after deducting issuance costs of RMB 52.14 million [1]. - As of June 30, 2025, the company has used RMB 535.18 million of the raised funds, leaving a balance of RMB 254.82 million [2]. Fund Management and Usage - The company has signed agreements with banks for the management of raised funds, ensuring that funds are stored in dedicated accounts under strict supervision [2]. - The company has invested in various projects, including a cosmetics smart manufacturing factory and marketing upgrades, with total investments amounting to RMB 932.65 million [3]. Cash Management Plan - The company intends to invest the idle funds in low-risk, principal-protected financial products, excluding securities investments [4][5]. - The cash management plan is valid for twelve months from the board meeting date and allows for rolling use of the RMB 200 million limit [1][6]. Impact on Daily Operations - The cash management initiative is designed to enhance fund efficiency without affecting the normal operations of fundraising projects or the company's main business [6][8]. - The decision-making process for this cash management plan has been deemed legal and compliant with relevant regulations [7][9].